40
Participants
Start Date
February 29, 2012
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
BMS-241027
Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
BMS-241027
Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
BMS-241027
Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
Placebo matching BMS-241027
Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
Local Institution, Berlin
The Clinical Trial Center, Llc, Jenkintown
Hospital Of The University Of Pennsylvania, Philadelphia
Penn Memory Center, Philadelphia
Local Institution, Toulouse
Compass Research, Llc, Orlando
Palm Beach Neurological Center Advanced Research Consultants, Palm Beach Gardens
The Ohio State University, Columbus
Michigan State University, East Lansing
Local Institution, Lille
Alexian Brothers Neurosciences Institute Clinical Research, Elk Grove Village
Local Institution, Heidelberg
Local Institution, Paris
Alpine Clinical Research Center, Inc., Boulder
Lifetree Clinical Research, Salt Lake City
Long Beach
Anaheim Clinical Trials Llc, Anaheim
Ucsf Memory And Aging Center, San Francisco
Associated Neurologists Of Southern Connecticut, P.C., Fairfield
Brigham And Women'S Hospital, Boston
Local Institution, London
Local Institution, Toronto
Local Institution, Greenfield Park
Local Institution, Stockholm
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY